Cidara Therapeutics to Participate in The Citizens Life Sciences Conference
Rhea-AI Summary
Cidara Therapeutics (Nasdaq: CDTX), a biotech company specializing in drug-Fc conjugate therapeutics through their proprietary Cloudbreak® platform, has announced their upcoming participation in The Citizens Life Sciences Conference.
The event details include:
- Conference: The Citizens Life Sciences Conference
- Date: Wednesday, May 7, 2025
- Time: 11:00 AM ET
- Format: Presentation
The presentation will be accessible via webcast, and a replay will be available in the Investors section of Cidara's website for at least 30 days. The company will also engage in one-on-one investor meetings during the event.
Positive
- Secured presentation slot at a major life sciences investment conference
- Company offers one-on-one investor meetings, indicating active investor relations efforts
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, CDTX declined 1.11%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in The Citizens Life Sciences Conference.
Details are as follows:
Event: The Citizens Life Sciences Conference
Date: Wednesday, May 7, 2025
Time: 11:00 AM ET
Format: Presentation
Webcast: https://wsw.com/webcast/jmp65/cdtx/1686102
A replay of the presentation will be available in the Investors section on the Company’s website at www.cidara.com. The replay of the presentation will be available for at least 30 days.
Cidara will also participate in one-on-one investor meetings during this event.
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced completion of Phase 2b enrollment in December 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
FAQ
When is Cidara Therapeutics (CDTX) presenting at The Citizens Life Sciences Conference 2025?
How can I watch Cidara Therapeutics' (CDTX) Citizens Conference presentation?
What is Cidara Therapeutics' (CDTX) main technology platform?
Will Cidara Therapeutics (CDTX) offer one-on-one meetings at the Citizens Life Sciences Conference?
Where can investors find the replay of Cidara's (CDTX) Citizens Conference presentation?
